CAM Capital: Funding, Team & Investors | Startup Intros

Loading organizations...

CAM Capital: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Aug 1, 2023	Kyverna Therapeutics	$60.0M Series B	Bain Capital Life Sciences, Craig Gordon	Access Biotechnology, Northpond Ventures, venBio, Westlake Village BioPartners, Sean Harper, Gilead Sciences, Insight Partners, jVen Capital, LYFE Capital, RTW Investments, Vida Ventures
May 16, 2022	Kriya Therapeutics	$270.0M Series C	Jim Momtazee	Bluebird Ventures, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital
Jan 10, 2022	AvengeBio	$45.0M Series A	Ben Askew, CAM Capital, Perceptive Xontogeny Venture Fund	Josh Richardson, Pappas Capital, Rock Springs Capital
Jan 1, 2022	Kyverna Therapeutics	$85.0M Series B	Northpond Ventures	Access Biotechnology, venBio, Westlake Village BioPartners, Sean Harper, Argentum Capital Partners, Mark Genovese, HealthCor, Hudson Bay Capital, Insight Partners, Intellia Therapeutics, jVen Capital, LYFE Capital, Niu (Chris) Liu, Fred Cohen
Nov 1, 2021	Antios Therapeutics	$75.0M Series B	EPIQ Capital Group, Craig Gordon	Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital
Sep 1, 2021	LEXEO Therapeutics	$100.0M Series B	Daniel Saul Sundheim, Joy Ghosh	Omega Funds, Alexandria Venture Investments, Gray's Creek Capital Partners, Invus, Janus Henderson Investors, Laurion Capital Management, Longitude Capital, Lundbeckfond Ventures, PBM Capital, Verition Fund Management, Woodline Partners
Jul 14, 2021	Kriya Therapeutics	$100.0M Series B	Jim Momtazee	Alumni Ventures, Amplo, Bluebird Ventures, Dexcel Pharma, Foresite Capital, Hongkou, JDRF, Narya Capital, QVT, Transhuman Capital, Woodline Partners
Apr 1, 2021	AltruBio	$63.0M Series A	—	aMoon Fund, BVF Partners
Apr 1, 2021	Arcellx	$120.0M Series C	Samsara BioCapital, CAM Capital	Genoa Ventures, Adage, Asymmetry Ventures, CaaS Capital Management, Cambrian Biopharma, LG Tech, NEA, Novo Holdings, Sixty Degree Capital, SR One, Surveyor Capital, Suvretta Capital Management, Takeda Ventures, Terra Magnum Capital Partners
Apr 1, 2021	Antios Therapeutics	$96.0M Series B	Guy Levy	Domain Associates, Michele Park, Pontifax Venture Capital, Sanofi Ventures, Adage Capital Management, Aisling Capital, Amzak Health, Delos Capital, Granite Point Capital, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital
Oct 1, 2020	Primmune Therapeutics	$27.0M Series A	CAM Capital, Amir Nashat	Domain Associates, Polaris Partners, BioBrit, BioRock Ventures, McDermott, Andrew Rubinstein, Samsara BioCapital
May 1, 2020	Palvella Therapeutics	$45.0M Series C	—	Samsara BioCapital, Adams Street Partners, Agent Capital, BioAdvance, BVF Partners, Scott Morenstein, Ligand Pharmaceuticals, Sean Nolan, Opaleye Management
Mar 2, 2020	Primmune Therapeutics	$7.0M Seed	—	Charlie Mcdermott, BioBrit, BioRock Ventures, Scott Morenstein
Apr 25, 2019	Satsuma Pharmaceuticals	$62.0M Series B	Wellington Management	Cormorant Asset Management, Eventide Asset Management, Lumira Ventures, Osage University Partners, RA Capital Management, SBI Investment, SNBL, Surveyor Capital, TPG Biotech
Apr 1, 2016	Kala Pharmaceuticals	$68.0M Series C	Gregory Grunberg, M.D.	5AM Ventures, Dave Maki, ARCH Venture Partners, Atlas Venture, Polaris Partners, CVF, Lux Capital, Jonathan Silverstein, Polaris Partners, Rajeev Shah, Chen Yu, Wellington Management
Dec 1, 2015	Velicept Therapeutics	$21.0M Series B	Scott Morenstein, David Hirsch	—